Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo - PubMed (original) (raw)

Affiliations

PMID: 12556556

Free article

Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo

Ella Atlas et al. Mol Cancer Res. 2003 Jan.

Free article

Abstract

Resistance of breast carcinomas to hormonal therapy is a clinical obstacle for the treatment of breast cancer. The molecular mechanisms and the factors involved in the progression of tumors from an estrogen (E2)-dependent to an E2-independent phenotype are not entirely understood. Heregulin (HRG) is a pleiotropic growth factor that binds to the erbB family of receptors, which are correlated with breast cancer progression and an aggressive phenotype in the breast carcinomas overexpressing the receptors. Previous studies in transgenic mice have shown that HRG is sufficient to induce mammary gland transformation and proliferation in the presence of hormonal stimulation. However, these studies did not address the important issue of the E2 independence that is part of the progression of breast cancer. In this study, we investigated the role of HRG in E2 independence. We were able to determine that HRG up-regulation was sufficient for the development of mammary tumors in the absence of E2 stimulation, a situation that mimics the progression of the human disease. We demonstrated that in ovariectomized nude mice, HRG induced E2 independence and antiestrogen resistance and promoted metastasis and preneoplastic transformation of the adjacent mouse mammary tissue. We show that one of the mechanisms by which HRG achieves the aggressive phenotype may be mediated via an increase in activated mitogen-activated protein kinase, an increase in a matrix-degrading enzyme, MMP-9, and the overexpression of vascular endothelial growth factors. The up-regulation of these genes occurred in the absence of any additional stimulation, in an autocrine manner. Our data provide new insights into the mechanisms of breast cancer progression in vivo, and reinforce the important role that HRG plays in this process.

PubMed Disclaimer

Cited by

Talin1 promotes HCC progression by regulating NRG1/PI3K/AKT pathway.
Liu J, Lu Y, Zheng B, Huang D, Song J, Wang B, Zheng S. Liu J, et al. Discov Oncol. 2024 Aug 20;15(1):360. doi: 10.1007/s12672-024-01243-2. Discov Oncol. 2024. PMID: 39162903 Free PMC article.
Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.
Yang L, Vander Steen T, Espinoza I, Cuyàs E, Verdura S, Menendez JA, Lupu R. Yang L, et al. Am J Cancer Res. 2022 May 15;12(5):2173-2188. eCollection 2022. Am J Cancer Res. 2022. PMID: 35693067 Free PMC article.
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment.
Lappano R, Todd LA, Stanic M, Cai Q, Maggiolini M, Marincola F, Pietrobon V. Lappano R, et al. Cancers (Basel). 2022 Jan 21;14(3):539. doi: 10.3390/cancers14030539. Cancers (Basel). 2022. PMID: 35158804 Free PMC article. Review.
HER2 Signaling in Breast Cancer.
Shin I. Shin I. Adv Exp Med Biol. 2021;1187:53-79. doi: 10.1007/978-981-32-9620-6_3. Adv Exp Med Biol. 2021. PMID: 33983573

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- eScholarship, California Digital Library, University of California
Other Literature Sources
- The Lens - Patent Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo - PubMed (original) (raw)